MedKoo Cat#: 100750 | Name: Porfimer Sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Porfimer, also known as Photofrin, is a photosensitizing agent used in photodynamic therapy (PDT) for various cancers, including esophageal and non-small cell lung cancer. It is a mixture of oligomeric porphyrins that accumulate preferentially in tumor tissues. Upon activation by red light (~630 nm), porfimer generates singlet oxygen and reactive oxygen species, leading to direct tumor cell death and vascular damage. Clinically, a typical intravenous dose is 2 mg/kg, followed by light exposure 40–50 hours later. In a Phase III trial for early-stage lung cancer, porfimer PDT achieved complete response rates of 50–60% in obstructive endobronchial lesions, with tumor necrosis and minimal systemic toxicity beyond local photosensitivity lasting 30–90 days.

Chemical Structure

Porfimer Sodium
Porfimer Sodium
CAS#87806-31-3 (sodium)

Theoretical Analysis

MedKoo Cat#: 100750

Name: Porfimer Sodium

CAS#: 87806-31-3 (sodium)

Chemical Formula:

Exact Mass:

Molecular Weight:

Elemental Analysis:

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
CL184116; CL-184116; CL 184116; DHE; dihematoporphyrin ether; Porfimer. Brand name: Photofrin; Photofrin II.
IUPAC/Chemical Name
3,3'-(12-(1-(1-(2,18-bis(2-carboxyethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethylporphyrin-7-yl)ethoxy)ethyl)-7-(1-hydroxyethyl)-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropionic acid
InChi Key
VAYJWFGRGMQINH-STKOUIOXSA-N
InChi Code
InChI=1S/C68H74N8O11/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50/h21-28,37-40,71-73,75,77-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86)/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-
SMILES Code
O=C(O)CCC1=C2/C=C3C(CCC(O)=O)=C(C)C(/C=C(N/4)/C(C)=C(C(O)C)C4=C\C5=N/C(C(C(OC(C6=C7/C=C8C(C)=C(C(O)C)C(/C=C(N/9)/C(C)=C(CCC(O)=O)C9=C\C%10=N/C(C(C)=C%10CCC(O)=O)=C\C(N7)=C6C)=N/8)C)C)=C5C)=C\C(N2)=C1C)=N/3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.  

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ito A, Kimura T, Miyoshi S, Ogawa S, Arai T. Photosensitization reaction-induced acute electrophysiological cell response of rat myocardial cells in short loading periods of talaporfin sodium or porfimer sodium. Photochem Photobiol. 2011 Jan-Feb;87(1):199-207. doi: 10.1111/j.1751-1097.2010.00846.x. Epub 2010 Nov 29. PubMed PMID: 21114668. 2: Pereira SP, Ayaru L, Ackroyd R, Mitton D, Fullarton G, Zammit M, Grzebieniak Z, Messmann H, Ortner MA, Gao L, Trinh MM, Spénard J. The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. Aliment Pharmacol Ther. 2010 Sep;32(6):821-7. doi: 10.1111/j.1365-2036.2010.04400.x. PubMed PMID: 20629974; PubMed Central PMCID: PMC2978022. 3: Yumita N, Han QS, Umemura S. Sonodynamically induced apoptosis with porfimer sodium in HL-60 cells. Anticancer Drugs. 2007 Nov;18(10):1149-56. PubMed PMID: 17893515. 4: Mino-Kenudson M, Ban S, Ohana M, Puricelli W, Deshpande V, Shimizu M, Nishioka NS, Lauwers GY. Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol. 2007 Mar;31(3):403-9. PubMed PMID: 17325482. 5: Stoev G, Stoyanov A, Shopova M, Dachev K. Identification of porphyrin modified photosensitizer porfimer sodium and its precursors by high performance liquid chromatography and mass spectrometry. J Chromatogr A. 2007 Mar 23;1145(1-2):141-8. Epub 2007 Jan 26. PubMed PMID: 17303147. 6: Ohmori S, Arai T. In vitro behavior of Porfimer sodium and Talaporfin sodium with high intensity pulsed irradiation. Lasers Med Sci. 2006 Dec;21(4):213-23. Epub 2006 Sep 22. PubMed PMID: 17024319. 7: Shah AK, Wolfsen HC, Hemminger LL, Shah AA, DeVault KR. Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett's dysplasia and mucosal carcinoma. Dis Esophagus. 2006;19(5):335-9. PubMed PMID: 16984528. 8: Houle JM, Clervoix N, Bain S, Spénard J. Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium. Clin Pharmacokinet. 2006;45(9):923-30. PubMed PMID: 16928153. 9: Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med. 2006 Jun;38(5):417-26. PubMed PMID: 16788928. 10: Panjehpour M, Overholt BF. Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia. Lasers Surg Med. 2006 Jun;38(5):390-5. PubMed PMID: 16788927.